Philip Morris International (PMI) said the U.S. Food and Drug Administration (FDA) has authorised the company to market its ZYN nicotine pouches with reduced-risk claims compared to cigarettes, marking the first such approval for a nicotine pouch product in the United States.
According to PMI, the FDA issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN, allowing the company to market the products with the claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
